PO.CL11.02 · 临床研究

Clinical outcomes of Ayurveda Rasayana therapy (ART) in advanced pancreatic cancer patients: A retrospective study

海报缩略图:Clinical outcomes of Ayurveda Rasayana therapy (ART) in advanced pancreatic cancer patients: A retrospective study
编号 1239 展板 13 时间 4/19 02:00–05:00 区域 Section 48 主讲 Mukta Marathe
分会场 Survivorship, Supportive Care, and Quality of Life in Oncology
查看完整资料 下载 PDF 登录后可访问当前开放资料 AACR 官方页面 ↗

作者与单位

Yogesh Bendale1, Priyanka Shirole1, Poonam Birari-Gawande1, Avinash Kadam1, Mukta Marathe2

1Rasayu Cancer Clinic, Pune, India,2AatharvaN Ayurved & Yog, LLC, Phoenix, AZ

摘要 Abstract

Purpose: A significant proportion, 25-60%, of pancreatic cancer patients cannot receive standard chemotherapy or surgery, usually due to poor performance status, advanced disease, or significant comorbidities. The median survival of these patients is only 3-6 months, and the primary therapeutic goals are improvement of Quality of Life (QoL) and extension of survival. This study evaluates the role of Ayurveda Rasayana Therapy (ART) in this category of patients. Method: We retrospectively analyzed data from 17 patients with advanced, inoperable pancreatic cancer who were ineligible for chemotherapy. Patients were treated exclusively with Ayurvedic Rasayana preparations primarily containing preparations like Heeraka Bhasma (diamond) , Suvarna Bhasma (gold) , and Tamra Bhasma (copper) , Shankha Bhasma (Conch) , Moutika Bhasma (Pearl) . Health-related QoL was assessed by the FACT-G questionnaire, and performance status was measured by the ECOG scale at baseline and on day 90. The patient's anorexia was measured by the Anorexia-Cachexia Scale (ACS). Results: The patients mean age was 62.75±9.14. Treatment significantly improved FACT-G overall quality of life scores (48±14.71 vs 56.35±10.85; p <0.05). ECOG performance status showed significant improvement as compared to baseline (2.29±0.84 vs 1.85±0.79; p <0.05). A significant reduction in anorexia was also noted (19±35 vs 28.35±8.20; p <0.05). Partial tumour response was recorded for two patients. The average survival seen in this group was 316±248.76, days which surpassed the expected range of 3 to 6 months. Conclusions: This preliminary data indicates that Ayurveda Rasayana Therapy may be a beneficial intervention to improve quality of life, reduce disease-related distress, and extend survival in pancreatic cancer patients with no standard treatment options. As these results are based on observations from a small sample size, they should be interpreted with caution and need further rigorous investigation.
利益披露 Disclosure
Y. Bendale, None.. P. Shirole, None.. P. Birari-Gawande, None.. A. Kadam, None.. M. Marathe, None.

在会议检索中打开